Product News
Molzym announces FDA Breakthrough Device Designation for its molecular diagnostic test system
FDA Breakthrough Device Designation for Sepsis, Joint & Implant Infections, Infective Endocarditis, Bacterial Meningitis
FDA Breakthrough Device Designation for Sepsis, Joint & Implant Infections, Infective Endocarditis, Bacterial Meningitis
In a Phase 3 trial, the vaccine was 100% effective and generally well tolerated in participants aged 12 to 15 years
Scientific, technological and communications excellence has been celebrated at the Virtual Cancer and Immunology Research Summit, with Logos Biosystems, INTEGRA Biosciences and Sartorius among those recognized
UN3373 compliant sample packaging solution
Discover how collaborative research between big pharma and academia is using the latest proteomics platforms to revolutionize drug discovery